By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Fibrocell Science, Inc. 

405 Eagleview Boulevard

Exton  Pennsylvania  19341  U.S.A.
Phone: 484-713-6000 Fax: 484-713-6001



Company News
Fibrocell (FCSC) To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference 7/8/2016 9:48:46 AM
Fibrocell (FCSC) Looking for Azficel-T Buyer and Lays Off Employees as Program Winds Down 6/30/2016 7:21:17 AM
Fibrocell (FCSC) Announces Initiation Of Patient Recruitment In Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 6/13/2016 8:05:33 AM
Fibrocell (FCSC) Tumbles as Lead Product Did Not Meet Primary Endpoints in Phase II Study 6/8/2016 7:35:48 AM
Fibrocell Science, Inc. Reports First Quarter 2016 Financial Results and Operational Highlights 5/5/2016 8:36:11 AM
Fibrocell Science, Inc. To Host Conference Call And Webcast On Thursday, May 5, 2016 To Discuss First Quarter 2016 Financial Results And Recent Operational Highlights 4/28/2016 8:17:15 AM
Fibrocell Science, Inc. Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma 4/25/2016 8:19:04 AM
Fibrocell Science, Inc. Announces Last Patient Visit For Primary Endpoint Analysis In Phase II Clinical Trial Of Azficel-T For The Treatment Of Vocal Cord Scarring 4/21/2016 8:26:35 AM
Fibrocell Science, Inc. And Intrexon Announce Allowance To Commence Phase I/II Trial For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 4/18/2016 10:20:06 AM
Fibrocell Science, Inc. To Present At The Alliance For Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day 3/15/2016 8:31:13 AM